Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

Company Overview - Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock [1][5] - The company is seeking U.S. FDA approval for its product Toraymyxin™ (PMX), a therapeutic hemoperfusion device that removes endotoxin from the bloodstream [5][6] Financial Activities - Spectral has filed a preliminary short form base shelf prospectus to qualify the distribution of up to $100 million in various securities over a 25-month period [2][3] - The specific terms of any offering will be established in a prospectus supplement filed with the applicable Securities Regulators [2] Clinical Development - PMX is already approved for therapeutic use in Japan and Europe, with over 360,000 uses to date [6] - The Tigris Trial is a confirmatory study of PMX, designed as a 2:1 randomized trial involving 150 patients [7] Market Context - Approximately 330,000 patients are diagnosed with septic shock in North America each year, indicating a significant market opportunity for the company's products [6]